These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 34877663)

  • 21. OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine.
    Argyriou AA; Dermitzakis EV; Xiromerisiou G; Vikelis M
    Toxins (Basel); 2022 Dec; 14(12):. PubMed ID: 36548744
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
    Chiang CC; Schwedt TJ
    Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double-blind studies.
    Ailani J; Pearlman E; Zhang Q; Nagy AJ; Schuh K; Aurora SK
    Eur J Neurol; 2020 Mar; 27(3):542-549. PubMed ID: 31595600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study.
    Manack Adams A; Hutchinson S; Engstrom E; Ayasse ND; Serrano D; Davis L; Sommer K; Contreras-De Lama J; Lipton RB
    J Headache Pain; 2023 Aug; 24(1):102. PubMed ID: 37537578
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current and emerging evidence-based treatment options in chronic migraine: a narrative review.
    Agostoni EC; Barbanti P; Calabresi P; Colombo B; Cortelli P; Frediani F; Geppetti P; Grazzi L; Leone M; Martelletti P; Pini LA; Prudenzano MP; Sarchielli P; Tedeschi G; Russo A;
    J Headache Pain; 2019 Aug; 20(1):92. PubMed ID: 31470791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-calcitonin gene-related peptide monoclonal antibodies for neuropathic pain in patients with migraine headache.
    Kang SA; Govindarajan R
    Muscle Nerve; 2021 Apr; 63(4):563-567. PubMed ID: 33347632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Onabotulinumtoxin-A: Previous Prophylactic Treatment Might Improve Subsequent Anti-CGRP Monoclonal Antibodies Response in Patients with Chronic Migraine.
    Ceccardi G; Schiano di Cola F; Caratozzolo S; Di Pasquale M; Bolchini M; Padovani A; Rao R
    Toxins (Basel); 2023 Nov; 15(12):. PubMed ID: 38133181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Future prophylactic treatments in migraine: Beyond anti-CGRP monoclonal antibodies and gepants.
    Do TP; Al-Saoudi A; Ashina M
    Rev Neurol (Paris); 2021 Sep; 177(7):827-833. PubMed ID: 34294458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of dual migraine therapy with CGRP inhibitors and onabotulinumtoxinA injections: case series.
    Toni T; Tamanaha R; Newman B; Liang Y; Lee J; Carrazana E; Vajjala V; Viereck J; Liow KK
    Neurol Sci; 2021 Dec; 42(12):5373-5376. PubMed ID: 34409517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity.
    Bigal ME; Walter S
    CNS Drugs; 2014 May; 28(5):389-99. PubMed ID: 24638916
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CGRP Monoclonal Antibodies for the Preventative Treatment of Migraine.
    Israel H; Neeb L; Reuter U
    Curr Pain Headache Rep; 2018 Apr; 22(5):38. PubMed ID: 29623520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort Study.
    Alex A; Vaughn C; Rayhill M
    Headache; 2020 Nov; 60(10):2454-2462. PubMed ID: 32969035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review.
    Sevivas H; Fresco P
    Eur J Med Res; 2022 Jun; 27(1):86. PubMed ID: 35659086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
    Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
    Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic migraine treatment: from OnabotulinumtoxinA onwards.
    Negro A; Curto M; Lionetto L; Giamberardino MA; Martelletti P
    Expert Rev Neurother; 2016 Oct; 16(10):1217-27. PubMed ID: 27310178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Direct cost and healthcare resource utilization of patients with migraine before treatment initiation with calcitonin gene-related peptide monoclonal antibodies by the number of prior preventive migraine medication classes.
    Foster SA; Hoyt M; Ye W; Mason O; Ford JH
    Curr Med Res Opin; 2022 May; 38(5):653-660. PubMed ID: 34761723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Onabotulinumtoxin A (ONA-BoNT/A) in the treatment of chronic migraine.
    Domitrz I; Sławek J; Słowik A; Boczarska-Jedynak M; Stępień A; Rejdak K; Gierczyński J; Rożniecki J
    Neurol Neurochir Pol; 2022; 56(1):39-47. PubMed ID: 34477213
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
    Schoenen J; Manise M; Nonis R; Gérard P; Timmermans G
    Rev Neurol (Paris); 2020 Dec; 176(10):788-803. PubMed ID: 32758365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CGRP pathway monoclonal antibodies for cluster headache.
    Chan C; Goadsby PJ
    Expert Opin Biol Ther; 2020 Aug; 20(8):947-953. PubMed ID: 32241175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Novel migraine treatment with CGRP-related monoclonal antibodies].
    Shibata M
    Rinsho Shinkeigaku; 2020 Oct; 60(10):668-676. PubMed ID: 32893246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.